Medistem Laboratories, Inc. (MDSM.OB) is aggressively moving forward with its stem cell therapy research.
MDSM is collaborating on pre-clinical research with the Lawson Health Research Institute in London, Ontario regarding the Company’s proprietary platform called Tolerostem(TM) in the fight against autoimmune diseases.
Subject to positive research results Medistem plans to submit an IND application to the FDA. The Tolerostem(TM) proprietary technology is designed to treat autoimmune diseases through reprogramming components of the immune system to stop attacking healthy tissue, while maintaining their role in fighting external pathogens.
Let us hear your thoughts below: